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Daily self-injecting of insulin and fre-quent self-monitoring of blood glu-cose (SMBG) are essential to ade-
quately manage insulin-requiring diabetes.
Extreme fear of self-injecting (FSI) insulin
(injection phobia) is likely to compromise
glycemic control as well as emotional well-
being. Likewise, fear of SMBG (finger prick)
can be a source of distress and may seriously
hamper self-management. There is evidence
to suggest that fear of blood and injury is
associated with less frequent self-testing
(1,2) and poor glycemic control (2). How-
ever, research concerning the etiology, preva-
lence, and treatment of FSI and fear of self-
testing (FST) in patients with diabetes is
scarce. To date, only a few studies, mostly
case reports, have been published on the
subject of FSI (3–8), and no research is
known to us on FST.
To quantify the level of FSI as well as
FST in adults with insulin-requiring dia-
betes, we developed a diabetes-specific
questionnaire, the Diabetes Fear of Injecting
and Self-Testing Questionnaire (D-FISQ),
which consists of 2 subscales, FSI and FST
(9,10). Subscale scores and a total score are
obtained. Preliminary results suggested sat-
isfactory psychometric properties. In the
present study, stability of the D-FISQ was
assessed over different periods of time, and
construct, discriminant, and convergent
validity were examined. Criterion-related
validity was tested by means of a behavioral
avoidance test (BAT), in which the actual
self-injecting and self-testing behaviors of
extreme scorers on the D-FISQ were exam-
ined. Moreover, we investigated the latent
factor analytic structure of the D-FISQ.
RESEARCH DESIGN AND 
METHODS
Study subjects and procedure
Reliability: internal consistency and test-
retest reliability. A composite question-
naire including the D-FISQ was sent to a
random sample of 3,000 patients (with
type 1 or 2 diabetes) drawn from ,40,000
members of the Dutch Diabetes Association
(DVN, Diabetesvereniging Nederland).
Inclusion criteria were 1) age .16 years
and 2) being on insulin therapy for a min-
imum of 6 months. The latter criterion was
chosen because we were interested in
FSI/FST that persists beyond the early
adaptation period. In total, 1,484 ques-
tionnaires were returned (49.5%); 12 ques-
tionnaires were excluded from data
analyses because they were not complete.
After exclusion of subjects not using insulin
(n = 197), 1,275 subjects remained, from
which a group of 252 subjects (sample A)
was randomly selected. In this sample,
internal consistency was assessed, as well as
several aspects of validity. A second set of
questionnaires, once more including the
D-FISQ, was sent to this sample after ,3
months to determine test-retest reliability of
the D-FISQ.
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Diabetes Fear of Injecting and 
Self-Testing Questionnaire 
A pschometric evaluation
O R I G I N A L  A R T I C L E
OBJECTIVE — To study the psychometric properties of the Diabetes Fear of Injecting and
Self-Testing Questionnaire (D-FISQ).
RESEARCH DESIGN AND METHODS — Two groups of patients were studied. Sam-
ple A consisted of 252 insulin-treated diabetes patients. Sample B incorporated 24 insulin-
treated patients with high scores ($95th percentile) on the D-FISQ. Test-retest correlations
were assessed in both samples. Discriminant and convergent validity of the D-FISQ were
assessed with questionnaires concerning fear of hypoglycemia, trait anxiety, and fear of bod-
ily injury, illness, or death. To evaluate criterion-related validity, sample B participated in a
behavioral avoidance test (BAT), in which the current level of avoidance of either self-inject-
ing or self-testing was determined. Exploratory factor analysis (EFA) was performed to study
whether 2 factors (fear of self-injecting [FSI] and fear of self-testing [FST]) could be detected.
RESULTS — Test-retest correlations ranged from 0.50 to 0.68 (P , 0.001). Correlations
between D-FISQ and fear of hypoglycemia, trait anxiety, and fear of bodily injury, illness, or
death ranged from 0.28 to 0.45 (P , 0.001). Patients who refused to do a BAT for self-inject-
ing or self-testing had higher scores on FSI (P = 0.095) and FST (P = 0.01). EFA yielded 2 sep-
arate factors, FSI and FST.
CONCLUSIONS — Results from this study support reliability and validity of the D-FISQ,
a self-report instrument that can be used for both clinical and research purposes.
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Reliability and validity of the D-FISQ
From the 1,275 subjects, patients who
scored in the $95th percentile on the FSI
and/or FST subscale were approached for
further research (n = 118; 36 patients scored
in the $95th percentile on both FSI and
FST). They were sent another composite
questionnaire on which they indicated
whether they would be willing to take part
in an interview. A total of 79 patients
(66.9%) returned this questionnaire, 50 of
whom said they were willing to be inter-
viewed (no statistically significant differ-
ences were found on sociodemographic
variables between volunteers [n = 50] and
refusers [n = 29] for the interview). Selective
sampling was applied. Our aim was to have
a balance in sex distribution in this sample
and to create diversity in FSI and FST
scores. Patients were contacted by tele-
phone and given further information on
the interview procedure, which included a
BAT. If the patient agreed to cooperate, an
appointment was made for the interview at
the university. To assess the current level of
FSI and FST, the patients filled out the
D-FISQ before the interview. Patients who
participated in the interview form sample B.
Validity. To assess construct validity, score
distribution as well as intercorrelations of the
D-FISQ and FSI and FST were considered in
sample A. Discriminant and convergent
validity were assessed by determining corre-
lations between the D-FISQ and question-
naires concerning trait anxiety and fear of
hypoglycemia (HFS-Worry). Furthermore,
the association between the D-FISQ and
fear of bodily injury, illness, or death, a sub-
scale of the Fear Survey Schedule III-R, was
determined. We expected moderate inter-
correlations between the questionnaires,
which would confirm an underlying sus-
ceptibility for anxiety/fear in patients.
Criterion-related validity of the D-FISQ
was assessed by a BAT in sample B. This is
a common procedure in behavioral sciences
to determine a subject’s level of avoidance of
a feared object or situation. A gradual step-
wise approach is formulated—from not
being in contact with the phobic stimulus at
all, to touching or handling it (11,12). A
patient acquires a BAT score according to
the number of steps that he or she is able to
complete. In our case, the maximum score
would be obtained when a patient was actu-
ally able to complete an insulin injection or
finger prick. Refusing to do the BAT would
be scored as a 0 (extreme avoidance). At the
end of the interview (if it was not already
clear), patients were asked which they
feared most, injecting or self-testing, and
whether they would be willing to perform
that task. Patients were, therefore, only
required to perform 1 BAT, namely for their
primary fear. Injections were performed
with an injection pen (NovoLet 1.5 ml or
NovoPen 3; Novo Nordisk Farma, Alphen
aan den Rijn, the Netherlands) the most
common insulin pens in the Netherlands)
with a saline solution provided by E.D.M.
Patients were asked to bring along their
own blood glucose monitoring equipment;
otherwise, one of the authors (E.D.M.) pro-
vided them with a blood glucose meter
(Acutrend Sensor Glucose; Boehringer
Mannheim, Almere, the Netherlands). The
BATs were videotaped and time-recorded.
Patients were also asked to fill in a tension
rating by means of a visual analog scale
(VAS) (ratings ranged from 0 to 10: 0, not
tense at all; 10, extremely tense) before and
after the BAT to indicate how tense they felt.
When the first BATs were performed, it
became clear that patients either performed
the task and completed it or refused alto-
gether. Therefore, BAT scores were dichoto-
mous: refused or completed. D-FISQ scores
obtained before the interview were linked to
the outcome of the BAT.
Factor analysis
An exploratory factor analysis (EFA) was
performed to evaluate the presence of the 2
factors, i.e., FSI and FST.
Instruments
Questionnaires used in the first booklet
were the D-FISQ (9,10) and the Dutch ver-
sions of the Problem Areas in Diabetes (13),
the Worry-Scale of the Hypoglycemia Fear
Survey (14,15), the trait scale of the State
Trait Anxiety Inventory (16,17), the 12-
item Well-Being Questionnaire (18,19), the
Diabetes Coping Measure (20), the Hospi-
tal Anxiety and Depression Scale (21), and
the Diabetes Quality of Life Measure (22).
The D-FISQ was developed by the
authors and consists of 2 separate 15-item
subscales, i.e., the FSI subscale and the FST
subscale. First findings indicated high inter-
nal consistency, with Cronbach’s a ranging
from 0.90 to 0.94. High scores in FSI and
FST coincided in ,40% of the cases (9). In
the present validation study, we took the
opportunity to add 4 items to both sub-
scales of the D-FISQ to ensure that all rele-
vant aspects of blood phobia were included.
These items concerned dizziness, fainting,
difficulty in concentrating, or becoming
nauseous when self-injecting or self-test-
ing, resulting in 2 subscales of 19 items.
Items were presented as statements and
were scored on a 4-point Likert scale, from
0 (almost never) to 3 (almost always). Sub-
scale scores were calculated by summation
(minimum score = 0, maximum score =
57). A total score could also be derived.
The Dutch version of the Worry-scale
of the Hypoglycemic Fear Survey (14,15)
was used, a diabetes-specific instrument
that detects the level of fear with respect to
hypoglycemic reactions (Cronbach’s a =
0.92). The Dutch adaptation of the State-
Trait Anxiety Inventory trait subscale
(16,17) was used to assess anxiety as a trait
(Cronbach’s a = 0.87–0.92).
The second booklet of questionnaires,
which was sent to people who scored in the
$95th percentile on FSI and/or FST,
included the following measures: the
Netherlands Personality Questionnaire (23)
and the Dutch versions of the Fear Survey
Schedule III-R (FSS-III-R) (24), the Becks
Depression Inventory (25), and the Symp-
tom Checklist 90 (26). FSS-III-R distin-
guishes 5 types of fears/phobias. One of its
subscales addresses fear of bodily injury, ill-
ness, or death (12 items, Cronbach’s a =
0.77–0.84) and includes items on fear of
needles and blood.
The study protocol was approved by
the Ethics Committee of the University
Hospital of the Vrije Universiteit Amster-
dam, and written informed consent was
obtained from the patients (sample B) for
the interview and the BAT procedure.
Statistical analyses
Statistical analyses were performed using
SPSS 7.5 for Windows (SPSS, Chicago)
(27). Values are expressed as means ± SD for
normally distributed data or as median with
range and interquartile range for skewed
data. Spearman’s rank correlation coeffi-
cients were calculated to determine associ-
ations between various variables, as well as
test-retest reliability. Analyses included
unpaired Student’s t tests and x2 tests. Cron-
bach’s a was determined for internal con-
sistency. Corrected item-total correlations
were obtained. P , 0.05 was considered to
be statistically significant, and P , 0.10
was regarded as a trend. As a prerequisite to
EFA in sample A, all items of the 2 subscales
were screened for their contribution to
the D-FISQ. Items with low variance
(,5% of scores .0) were excluded; excep-
tions were made for items that were con-
sidered to be highly clinically relevant. In
EFA, items loading $|0.40| were accepted
(28). In our earlier research, self-injecting
and self-testing were found to be signifi-
cantly correlated (9), therefore oblique rota-
tion (direct oblimin) was considered
appropriate (28). Mann-Whitney U tests
were performed to examine group differ-
ences in D-FISQ scores.
Internal consistency was determined of
the factors found in EFA. Moreover, k-coef-
ficients were used to determine the measure
of agreement between the D-FISQ and the
factors found in EFA.
RESULTS — Characteristics of samples
A and B are shown in Table 1. Of the 50 sub-
jects who could be approached for an inter-
view in view of their D-FISQ score and were
willing to cooperate, 24 patients were
selected and agreed to participate (sample
B). The remaining 26 nonparticipants in the
interview had a significantly longer duration
of insulin use (P , 0.05), but otherwise no
significant differences were found on
sociodemographic variables between partic-
ipants and nonparticipants in the interview.
No significant differences were found
on sociodemographic characteristics
between samples A and B, although a trend
exists (P , 0.10) toward more female
patients, shorter durations of insulin use,
and lower numbers of self-reported self-
tests in the fearful group. Response to the
3-month retest was 90.5% (n = 228, 49.1%
men, mean age 48.5 ± 15.4 years, 58.3%
with type 1 diabetes).
Reliability: internal consistency and
stability
Internal consistency (Cronbach’s a) for the
respective subscales, as calculated in sam-
ple A, were 0.89 (FSI) and 0.97 (FST).
No statistically significant difference in
mean scores was found between test and
retest on FSI or FST (data not shown).
Spearman’s correlation between test and
retest was 0.58 (P , 0.001) for FSI and
0.50 (P , 0.001) for FST after a 3-month
interval. Because of skewed score distribu-
tions, Spearman’s r was also determined
for the group that scored .0 on both test
and retest; correlations were 0.66 (n = 30,
P , 0.01) for FSI and 0.51 (n = 36, P ,
0.01) for FST.
Test-retest reliability was also deter-
mined in sample B (n = 24), with a mean
time interval of 15 months (range 11–20).
Spearman’s correlation between the 2 mea-
surements was 0.68 (P , 0.001) for FSI
and 0.50 (P , 0.01) for FST. In both sam-
ples A and B, there was no significant rela-
tionship (Spearman r) between duration of
diabetes/insulin use and the difference in
scores over time (data not shown).
Validity
Construct validity. As expected, FSI and
FST scores in sample A showed a highly
skewed distribution. A total of 191 sub-
jects (75.8%) obtained a score of 0, which
is the lowest possible score, on FSI
(interquartile range [IQR]: 0,0); 176
patients (69.8%) scored 0 on FST (IQR:
0,1). No statistically significant differences
were found between men and women on
FSI/FST scores. Spearman’s correlations
between the D-FISQ and its subscales were
0.79 (FSI-D-FISQ), 0.91 (FST-D-FISQ),
and 0.56 (FSI-FST) (P , 0.01).
Discriminant and convergent validity.
Spearman’s correlations between the
D-FISQ and its subscales and trait anxiety
ranged from 0.31 to 0.45 (P , 0.001).
Spearman r’s with HFS-Worry were
0.30–0.36 (P , 0.001). Correlations
between D-FISQ scales and the FSS-bodily
injury, illness, or death subscale varied from
0.28 to 0.32 (P , 0.001).
Criterion-related validity. FSI scores of
the patients who participated in the BAT
(n = 24) on the self-injecting subscale
ranged from 0 to 26; scores on the self-test-
ing subscale (FST) ranged from 2 to 44.
Fear of self-injecting
A total of 7 subjects of the 24 interviewees
indicated that they experienced most prob-
lems with self-injecting. They were therefore
asked if they would perform a self-injection
in the BAT with an insulin pen containing a
saline solution. The FSI scores (at the time
of the interview) of these 7 patients ranged
from 0 to 26. The 2 highest-scoring patients
(scores of 25 and 26) stated they were
unable to perform the behavioral test
because of anxiety. Both patients showed a
marked increase in FSI score (.10 points)
since the previous completion of the D-
FISQ of ,1 year earlier. Furthermore, these
2 patients had higher scores on FSI than
patients who completed the BAT (Mann-
Whitney U test, Z = 21.94, P = 0.095).
The other 5 patients were able to com-
plete the BAT. Their FSI scores ranged from
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Table 1—Sample characteristics
Variable Sample A Sample B
n 252 24
Men (%) 49.2 29.2 
Age (years) 47.9 ± 15.4 44.5 ± 16.7
Type 1 diabetes (%) 60.7* 45.8*
Diabetes duration (years)
0–5 (%) 19.4 29.2
6–10 (%) 18.3 20.8
11–20 (%) 34.1 33.3
$21 (%) 27.0 16.7





HbA1c (self-reported) 7.8 ± 1.7† 7.8 ± 1.9†
Self-injection rate per day (%)
1–2 31.7 41.7‡
$3 67.5 54.3





Data are n, means ± SD, or %. Percentages do not add up because of missing values. All patients were insulin-
treated. *Patients ,40 years of age at the time of diagnosis and who were treated with insulin from diagnosis
were regarded as type 1 diabetic patients. Patients who did not meet these criteria were considered type 2 dia-
betic patients. †Only 64.3% of sample A and 50.0% of sample B reported their HbA1c levels. ‡One patient used
an insulin pump.
0 to 13; 3 patients’ scores had dropped
slightly (1–3) compared with the previous
D-FISQ scores, and 1 patient reported that
he did not experience fear anymore (score
dropped from 11 to 0). Tension ratings
ranged from 0.4 to 5.8 (mean 3.3). Mean
time needed to complete the injection was
22 s (range 12–33).
Fear of self-testing
Of the 24 patients participating in the inter-
view, 17 patients indicated that they were
most anxious about self-testing. They were
therefore requested to perform a self-test in
the BAT. The FST scores of these 17
patients ranged from 2 to 44. A total of 4
patients were not able to perform a self-test
in the BAT, with FST scores in the range of
20–44. Since the previous D-FISQ com-
pletion, in 3 of the cases their scores had
increased (2–20 points), and 1 patient’s
score dropped from 25–20. These 4
patients who declined to do the BAT scored
significantly higher on FST than patients
who did complete the test (Mann-Whitney
U test, Z = 22.49, P = 0.01). The remain-
ing 13 patients were all able to complete
the BAT (mean tension rating 3.7). Of the
remaining patients, 3 had relatively high
scores of .20 (range 21–29, 6–18 points
higher than the first D-FISQ measure-
ment), 2 of whom reported tension ratings
of 9.3 and 6.5. The third patient reported a
tension rating of only 3.5; however, she
needed nearly a minute (57 s) to perform a
self-test (mean time needed for SMBG = 19
± 15 s, not including waiting time for read-
ing the result).
The FST scores of the other 10 subjects
ranged from 2 to 15; 7 scores had
decreased since the last D-FISQ (2–11
points), 2 scores had increased (1 and 4
points). Tension ratings were 0.3–7.2.
Factor analysis
Before EFA, items with low variance
(,5% of scores .0) were excluded,
among which were also the 4 items that
had been added to both original subscales.
The 2 items “I feel afraid when I have to
inject myself/when I have to prick my fin-
ger” did not meet the 5% criterion but
were not excluded for clinical reasons. In
total, 17 items remained for EFA (Table 2).
Two forced factors were calculated in EFA,
resulting in 2 factors of, respectively, 6 and
11 items, which accounted for 39.5 and
14.0%, respectively, explained variance
before rotation (Table 2). The 2 factors were
evaluated for internal consistency. Corrected
item-total correlations ranged from 0.55 to
0.72 in factor 1 and from 0.48 to 0.73 in
factor 2, and Spearman r correlation
between the 2 factors was 0.57 (P , 0.01).
Cronbach’s a of factor 1 (0.81) and factor 2
(0.88) were satisfactory. The measure of
agreement for dichotomized scores (at 95%
level) was determined between D-FISQ
subscales and the respective factors derived
from EFA. k Coefficients between these
dichotomized scores were 0.84 (FSI [factor
1]) and 0.83 (FST [factor 2]), respectively,
(both P , 0.001). Using a 95% cutoff point
on these factor scores, the EFA factors iden-
tified all patients in the total population
who scored on or above the scores of the
BAT refusers on FSI or FST.
CONCLUSIONS — Results from this
study substantiate earlier research in sup-
porting the psychometric properties of
the D-FISQ. Homogeneity of the D-FISQ
may be considered high, and test-retest
reliability for FSI was satisfactory. We found
moderate test-retest correlations for FST,
suggesting that FST is less stable over time
than FSI. To further explore the fluctua-
tions in FST, a test-retest procedure for FST
over a shorter period of time (i.e., 1–2
weeks) may prove useful. Validity of the
D-FISQ was supported by the distribution
of D-FISQ scores and the moderate corre-
lations with fear of hypoglycemia and trait
anxiety, corroborating our earlier findings
(9); these moderate intercorrelations may
be demonstrating a common fear suscepti-
bility underpinning the specific constructs
of the questionnaires. The modest associa-
tion found between D-FISQ scores and the
generic phobia questionnaire FSS-III-R
substantiates the need for a diabetes-spe-
cific instrument. What is more, results from
the EFA bear out the existence of separate
scales—FSI and FST—2 specific fears that
appear to be intercorrelated but are clearly
2 different constructs.
Data from the BAT support criterion-
related validity of the D-FISQ. For the BAT,
we relied on observation of behavior and
self-reported anxiety. Although physiologi-
cal arousal as a consequence of anxiety
during the BAT can be determined (e.g.,
heart rate, galvanic skin response, blood
pressure), we decided not to use these
methods, because parasympathetic reac-
tions can be affected by diabetes and results
would therefore be difficult to interpret.
Patients who refused the BAT had
higher FSI/FST scores than patients who
managed to complete the BAT. The differ-
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Table 2—Forced 2-factor solution after exploratory factor analysis of 17 items of the D-FISQ
Item content Factor 1 FSI Factor 2 FST Communality
When I have to inject myself:
I become restless 0.75 0.58
I feel tense 0.83 0.74
I feel afraid 0.65 0.38
I worry about it 0.67 0.46
I feel nervous 0.72 0.63
I brood about it 0.50 0.40 0.52
I try to postpone it 0.56 0.38
I get angry 0.48 0.38
When I have to prick my finger:
I become restless 0.70 0.57
I try to avoid it 0.72 0.49
I feel tense 0.62 0.52
I feel afraid 0.77 0.64
I worry about it 0.73 0.57
I feel nervous 0.65 0.61
I brood about it 0.74 0.59
I try to postpone it 0.76 0.53
I get angry 0.73 0.51
Eigenvalue before rotation 6.7 2.3
Eigenvalue after rotation 6.0 4.2
% Variance before rotation 39.5 14.0
Oblimin rotation was used. Loadings ,u0.40u are not shown.
ence in scores between those who refused
and those who completed the BAT was sig-
nificant for FST but did not reach signifi-
cance for FSI, which may be because of the
small number of subjects.
It should be noted that being able to
perform the BAT does not discern whether
a patient actually adheres to his or her reg-
imen in daily life. No difference was found
in HbA1c between samples A and B, but
these data concern self-reported HbA1c val-
ues, with a large number of missing data.
However, a trend was found toward patients
from sample B (extreme scorers) performing
fewer self-tests than sample A. More
research is warranted to address both the
psychological and glycemic consequences
of FSI and FST in patients with diabetes.
We consider the FSI and FST subscale
scores to be of high clinical and research
value, but it seems less useful to calculate a
total score, given the fact that high scores
on FSI and FST overlap in only 40% of
the cases (9).
Results from the EFA suggest that the
D-FISQ can be shortened, with Cronbach’s
a’s for both subscales somewhat lower, but
still highly satisfactory (29). Also, there is a
satisfactory level of agreement between the
D-FISQ and the EFA factors. Moreover,
none of the patients scoring at the level of
BAT refusers would be missed when using
a 95% cutoff point in the shortened ver-
sion. Further research into the clinical use-
fulness of the potential short version of the
D-FISQ is warranted.
In conclusion, the results of the present
study support validity and reliability of the
D-FISQ, a brief, easy-to-administer self-
report questionnaire that may prove useful
for both researchers and clinicians working
with insulin-treated diabetes patients.
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